MKMichelle King

Michelle King

*This is an algorithmically generated author record based on publicly available information.

Michelle King has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The SCRIPT Trial: A Randomised Controlled Trial of a Polygenic Risk Score to Tailor Colorectal Cancer Screening in Australian General Practice

    by Sibel Saya, Patty Chondros, Matthew Thoenig, Rachel Brooks, Adrian Laughlin, Madeline Luke, Georgia Ramsay, Richard De Abreu Lourenco, Antonio Ahumada-Canale, Floriy La Rocca, et al.

    Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.

  • Population‐based prostate cancer outcomes registries – what have we learned and where are we heading?

    by Wee Loon Ong, Krupa Krishnaprasad, Jonathan Bensley, Michelle Steeper, Kerri Beckmann, Sibilah Breen, Michelle King, Stephen Mark, Michael O'CAllaghan, Manish Patel, et al.


  • Open Access

    The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

    by Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Jane Gunn, Timothy F. Chen, Thomas M. Polasek, Elise Dettmann, Rachel Brooks, et al.

    Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.


  • Open Access

    Oral Health Professionals’ and Patients’ Opinions of Type-2 Diabetes Screenings in an Oral Healthcare Setting

    by Rodrigo Mariño, Andre Priede, Michelle King, Geoffrey G. Adams, Maria Sicari, Mike Morgan

    Objectives: As part of an evaluation of an oral healthcare practice-based model that identifies patients with prediabetes or type-2 diabetes (T2D), this study reports on the experiences and opinions of oral health professionals and patients on the screening program. Methodology: Urban and rural oral healthcare practices were invited to participate. Participating practices invited eligible patients to participate in the screening program. Patients were categorised as low, intermediate, or high-risk for prediabetes/T2D. Patients in the intermediate or high-risk category were referred to their general practitioner (GP) for further investigation. Post-screening surveys were used to assess acceptability, barriers and facilitators of the screening program among participating oral health professionals (OHP) and patients. Results: The post-screening survey was completed by 135 patient, and 38 OHPs (i.e., dentists, dental hygienists, oral health therapists). the majority of OHPs (94.6%) who delivered the protocol were satisfied with the approach. Most patients reported satisfaction with the approach (73.2%) and would recommend it to others. Several barriers for implementation were identified by OHPs and patients. Conclusion: OHPs feedback indicated that the screening model was generally acceptable. The feedback from patients following their participation in this study was overwhelmingly positive, indicating that the screening protocols were accepted by patients.

  • Open Access

    Oral health professionals screening for undiagnosed type-2 diabetes and prediabetes: the iDENTify study

    by Rodrigo Mariño, Andre Priede, Michelle King, Geoffrey G. Adams, Maria Sicari, Mike Morgan

    Background: As part of an evaluation of an oral healthcare practice-based model that identifies patients with prediabetes or type-2 diabetes, this study reports on the proportion of patients identified with clinically confirmed type-2 diabetes (T2D)/prediabetes and barriers of implementation of the model. Methodology: Urban and rural oral healthcare practices were invited to participate. Participating practices invited eligible patients to participate in the screening program using the Australian Type-2 Diabetes Risk Assessment Tool (AUSDRISK). Participants were categorised as low, intermediate, or high-risk for prediabetes/T2D. Patients in the intermediate or high-risk category were referred to their General Medical Practitioner (GP) for further investigation. Results: Fifty-one oral healthcare practices and 76 Oral Health Professionals (OHP) participated (60 Dentists, 8 Dental Hygienists, 8 Oral Health Therapists). 797 patients were screened; 102 were low-risk; 331 intermediate-risk; and 364 high-risk for T2D. Of the 695 participants in the intermediate or high-risk groups, 386 (55.5%) were referred to their GP for T2D assessment. Of them, 96 (25.0%) results were returned to OHPs. Of the returned results, six were (6.3%) diagnosed with pre-T2D. Conclusion: Patients found to have undiagnosed T2D/prediabetes (6.3%) were within the expected range reported in the literature. Findings indicate that identifying individuals at an elevated risk of having or developing T2D is effective, feasible and could be incorporated into oral healthcare settings. However, this integration may require additional OHPs training and education to ensure that patients at elevated risk of T2D are referred for further assessment.


  • Open Access

    Attitudes and opinions of Oral healthcare professionals on screening for Type-2 diabetes

    by Rodrigo Mariño, Andre Priede, Michelle King, Geoffrey G. Adams, Diego Lopez

    Background: As part of a larger study on the identification of undiagnosed Type 2 diabetes (T2D), and prediabetes patients in dental settings, this study explored oral healthcare professionals’ (OHP) attitudes with respect to the relevance and appropriateness of screening for prediabetes/T2D in general oral healthcare settings. It also aims to gain a deeper understanding of OHPs’ concerns and perceived barriers to screening for T2D. Methods: Semi-structured interviews were conducted with 11 OHPs: eight dentists, two dental hygienists and one oral health therapist. Interviews were audio recorded, transcribed verbatim and analysed using thematic analysis. Results: Themes that emerged from the interviews were organised under three major categories: 1) Implementation: OHPs willingness to screen for prediabetes/T2D; 2) Barriers to implementation of screenings; subdivided into: a) lack of knowledge and formal training about T2D screening methodology; b) concerns about patients’ awareness and acceptance of T2D screening in oral healthcare settings; c) costs and reimbursement for the time and resources required to screen patients; and d) legal and scope of practice; and 3) Collaboration and communication between OHPs and General practitioners (GP). Conclusions: The oral healthcare setting was considered as appropriate for medical screening, and OHPs were willing to participate in screening for prediabetes/T2D. Nonetheless, for the successful implementation of a screening programme, several barriers need to be addressed, and effective medical screening would require collaboration between oral health and medical and other health professionals, as well as clarification of legal and reimbursement issues.